Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Inclusion Criteria:

- All patients ≥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete
pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma,
intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors,
without an invasive component; or other benign pancreatic disease will be eligible.

Exclusion Criteria:

- The presence of metastatic disease or disease that precludes resection

- Receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months
of being enrolled in the study

- INR >2

- Known clotting factor deficiency or hypercoagulable state

- Any patient with the need or anticipated need for full anti-coagulation during
hospitalization for the resection.

- Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to
resection.

- IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion
for invasive component Additionally, if at the discretion of the operating surgeon,
blood collection would lead to undue morbidity, the patient will be excluded and
replaced